If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,553.00    29.00 (1.90%)
Bid:
1,552.00
Ask:
1,553.00
Spread: 1.00 (0.064%)
Market Cap: £3.27b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

17 Dec 2007 14:05

Hikma Pharmaceuticals Plc17 December 2007 For Immediate Release 17 December 2007 Notification of transaction by a Director/PDMR LONDON, 17 December 2007 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of theCompany, has today notified the Company of the sale of 320,000 ordinary sharesof 10 pence each in the capital of the Company, received by him pursuant to anexercise of share options in the Company on 15 October 2007. The sale was made in London at a price of 498.0 pence per share and was executedon 14 December 2007. The shares sold represented 0.187% of the outstanding sharecapital of the Company, and following the sale Mr Darwazah remains interested in1,706,506 ordinary shares, representing 0.999% of the share capital of theCompany. Mr. Darwazah is both a director and a Person Discharging ManagerialResponsibility in respect of the Company, and the above notification relates toDTR 3.1.4R(1)(a) and other Listing Rules. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary Susan Ringdal +44 20 7399 2760 Investor Relations Director Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
19th Aug 20156:28 pmRNSDirector/PDMR Shareholding
19th Aug 20157:00 amRNSInterim Results
28th Jul 20157:00 amRNSAcquisition
14th Jul 201511:12 amRNSTotal Voting Rights
18th May 201510:30 amRNSHikma Founder Samih Darwazah passes away
18th May 201510:00 amRNSDirector/PDMR Shareholding
15th May 20151:25 pmRNSDirector/PDMR Shareholding
14th May 20154:27 pmRNSResult of AGM
14th May 20157:00 amRNSAGM Trading Update
12th May 20159:00 amRNSHikma launches caffeine citrate injection
15th Apr 20159:47 amRNSHolding(s) in Company
10th Apr 20153:19 pmRNSTotal Voting Rights
10th Apr 20157:00 amRNSDirector/PDMR Shareholding
9th Apr 201511:16 amRNSAnnual Information Update
9th Apr 201510:51 amRNSAnnual Financial Report
7th Apr 20153:03 pmRNSBlocklisting Interim Review
1st Apr 20155:13 pmRNSHikma prices debut $500 million five-year eurobond
31st Mar 20153:27 pmRNSStabilisation Notice
25th Mar 201512:23 pmRNSFixed income investor meetings
19th Mar 20151:45 pmRNSDirector/PDMR Shareholding
13th Mar 201511:34 amRNSHolding(s) in Company
11th Mar 20157:00 amRNSFinal Results
27th Jan 20152:13 pmRNSHikma Delivers Insights at World Economic Forum
23rd Jan 201511:44 amRNSDirector Declaration
21st Jan 201511:19 amRNSNotification of major interest in shares
15th Jan 201510:04 amRNSBlocklisting Interim Review
12th Jan 20157:00 amRNSHikma to launch colchicine 0.6mg capsules
7th Jan 201511:11 amRNSTotal Voting Rights
12th Nov 201412:14 pmRNSDirector/PDMR Shareholding
11th Nov 20141:22 pmRNSTotal Voting Rights
7th Nov 201411:12 amRNSNotification of major interest in shares
6th Nov 20147:00 amRNSDirectorate Change
6th Nov 20147:00 amRNSInterim Management Statement
24th Oct 20147:00 amRNSHikma announces receipt of Warning Letter from FDA
20th Oct 20145:18 pmRNSDirector/PDMR Shareholding
10th Oct 201411:44 amRNSStatement re Colchicine
10th Oct 20147:00 amRNSDirector/PDMR Shareholding
6th Oct 20143:58 pmRNSBlocklisting Interim Review
6th Oct 201411:23 amRNSTotal Voting Rights
30th Sep 20146:13 pmRNSRegulatory Approval Colchicine
17th Sep 20147:00 amRNSAcquisition
20th Aug 20144:00 pmRNSDividend Declaration
20th Aug 20147:00 amRNSInterim Results
7th Aug 20144:05 pmRNSNotice of Interim Results Announcement
28th Jul 20149:01 amRNSDirector/PDMR Shareholding
24th Jul 20149:08 amRNSAcquisition
15th Jul 20143:35 pmRNSAcquisition
14th Jul 20143:41 pmRNSTotal Voting Rights
27th Jun 20144:07 pmRNSDirector/PDMR Shareholding
23rd Jun 20142:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.